Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?

Why are Trump’s new tariffs targeting EU and Mexico? How did Bitcoin reach a record high again? Why is Meta investing billions in AI infrastructure? What caused Tesla’s Autopilot legal trial in Florida? How will Walmart's water bottle recall impact sales? Why is Starbucks mandating office return four days weekly? What effect will Trump’s Patriot missile plan have on Ukraine?

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?

benzinga.com/analyst-stock-ratings/analyst-color/25/07/46400278/is-bristol-myers-squibb-still-an-undervalued-biopharma-play

Bristol-Myers Squibb & Co. (NYSE:BMY) is gearing up to announce its second-quarter 2025 earnings on July 31, with expectations for adjusted earnings of $1.585 per share on sales of $11.31 billion, according to data from Benzinga Pro.
While revenue and underlying earnings per share…

This story appeared on benzinga.com, 2025-07-14 17:52:06.